Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients
Status:
Recruiting
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
In North America, the number of new cases of prostate cancer increases every year. Many
efforts have been made to develop more efficient and safer curative treatments for high risk
prostate cancer patients.
This phase III clinical trial is designed to compare the safety of a standard pelvic external
beam radiation therapy (EBRT) combined with a high dose rate brachytherapy (HDRB) boost
(direct insertion of radiation source over a period of minutes via flexible needles
temporarily inserted in the prostate) to a shorter course of hypofractionated dose escalation
radiotherapy (larger radiation dose per daily treatment) in patients with high risk prostate
cancer.
The investigators plan to recruit 296 patients across Quebec who will be randomized in either
treatment plan.